Asset Details
Do you wish to reserve the book?
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
Do you wish to request the book?
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
2012
Overview
Background
Frequent exacerbations induce a high burden to Chronic Obstructive Pulmonary Disease (COPD). We investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with COPD
.
Methods
In 373 patients, we evaluated diary cards for symptoms, Peak Expiratory Flow (PEF), and salbutamol use and assessed their course during exacerbations.
Results
There were 492 exacerbations in 224 patients. The level of symptoms of cough, sputum, dyspnea and nocturnal awakening steadily increased from 2 weeks prior to exacerbation, with a sharp rise during the last week. Symptoms of cough, sputum, and dyspnea reverted to baseline values at different rates (after 4, 4, and 7 weeks respectively), whereas symptoms of nocturnal awakening were still increased after eight weeks. The course of symptoms was similar around a first and second exacerbation. Increases in symptoms and salbutamol use and decreases in PEF were associated with a higher risk to develop an exacerbation, but with moderate predictive values, the areas under the receiver operating curves ranging from 0.63 to 0.70.
Conclusions
Exacerbations of COPD are associated with increased symptoms that persist for weeks and the course is very similar between a first and second exacerbation. COPD exacerbations are preceded by increased symptoms and salbutamol use and lower PEF, yet predictive values are too low to warrant daily use in clinical practice.
Publisher
BioMed Central,BioMed Central Ltd,Nature Publishing Group,BMC
Subject
/ Albuterol - analogs & derivatives
/ Androstadienes - therapeutic use
/ Bronchodilator Agents - therapeutic use
/ CCQ
/ Chronic obstructive pulmonary disease
/ Complications and side effects
/ COPD
/ Disease
/ Female
/ Fluticasone-Salmeterol Drug Combination
/ Glucocorticoids - therapeutic use
/ Humans
/ Lungs
/ Male
/ Medicine
/ Pneumology/Respiratory System
/ Pulmonary Disease, Chronic Obstructive - drug therapy
/ Pulmonary Disease, Chronic Obstructive - physiopathology
/ Sleep
/ Symptoms
